Welcome to our dedicated page for Arrivent Biopharma SEC filings (Ticker: AVBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ArriVent BioPharma, Inc. (AVBP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ArriVent is a Nasdaq-listed, clinical-stage biopharmaceutical company, and its filings offer insight into the development of firmonertinib and its antibody-drug conjugate pipeline, as well as its capital structure and governance.
Through current reports on Form 8-K, ArriVent reports material events such as quarterly financial results, interim and final clinical data updates for firmonertinib in EGFR exon 20 insertion and PACC mutant non-small cell lung cancer (NSCLC), public offerings of common stock and pre-funded warrants, and collaboration agreements. These filings also confirm that ArriVent’s common stock trades on The Nasdaq Stock Market LLC under the symbol AVBP and identify the company as an emerging growth company.
Investors can use this page to review how ArriVent describes its pivotal Phase 3 trials like FURVENT and ALPACCA, its Phase 1b FURTHER study, and regulatory milestones such as FDA Breakthrough Therapy Designation and Orphan Drug Designation for firmonertinib. Filings may also discuss pipeline assets such as ARR-217 (MRG007), a CDH17-targeted ADC, and outline how equity offerings and cash resources are intended to support ongoing research and development.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information on clinical trial status, financial condition, and corporate actions. Real-time updates from EDGAR, along with structured access to 8-Ks and other core filings, allow users to monitor changes in ArriVent’s development programs, financing activities, and governance without manually parsing every page.
ArriVent BioPharma, Inc. reported that it will present two preclinical poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego from April 17-22. The information is furnished under Regulation FD and an accompanying press release is included as an exhibit.
One poster covers preclinical findings for EGFR inhibitor firmonertinib, including high-resolution crystal structure data that support an ongoing pivotal Phase 3 study in frontline EGFR exon 20 insertion mutant non-small cell lung cancer. The other focuses on ARR-002, a novel dual-target MUC16/NaPi2b tetravalent antibody drug conjugate for ovarian and endometrial cancers, describing its preclinical characterization and planned advancement toward clinical evaluation, with additional data to be highlighted in an oral mini-symposium presentation.
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on cancers driven by EGFR and related mutations, especially non-small cell lung cancer (NSCLC). Its lead oral drug, firmonertinib, targets both classical and uncommon EGFR mutations, including exon 20 insertions and PACC mutations.
Firmonertinib, licensed globally (ex‑Greater China) from Allist, has shown high response rates in Phase 1b studies. In treatment‑naive EGFR exon 20 insertion NSCLC, the FAVOUR trial reported a confirmed overall response rate of 79% and median duration of response of 15.2 months at 240 mg once daily. In PACC‑mutant NSCLC, the FURTHER trial reported a 68.2% confirmed response rate and 16.0‑month median progression‑free survival at 240 mg.
The company is running two pivotal global Phase 3 trials: FURVENT in first‑line exon 20 insertion NSCLC against platinum‑pemetrexed, and ALPACCA in first‑line PACC‑mutant NSCLC against investigator’s choice of osimertinib or afatinib. Firmonertinib has Breakthrough Therapy Designation for first‑line EGFR exon 20 insertion NSCLC and Orphan Drug Designation for NSCLC with several HER‑family mutations.
Beyond firmonertinib, ArriVent is building an oncology pipeline of antibody‑drug conjugates (ADCs). It is developing ARR‑217 (MRG007), a CDH17‑targeting ADC for gastrointestinal tumors under license from Lepu Biopharma, and advancing preclinical ADC candidate ARR‑002 via a platform collaboration with Aarvik. An additional ADC collaboration with Alphamab aims to generate novel ADCs using proprietary linker‑payload and glycan‑conjugation technologies.
ArriVent reported an aggregate market value of common stock held by non‑affiliates of $762,664,165 as of June 30, 2025, and 44,201,622 shares of common stock outstanding as of March 4, 2026.
ArriVent BioPharma, Inc. reported full year 2025 results and updated its oncology pipeline. The company is advancing firmonertinib through two global Phase 3 trials in first-line non-small cell lung cancer with uncommon EGFR mutations, with topline data from the exon 20 insertion study expected in mid-2026 and a projected cash runway into 3Q 2027.
For the year ended December 31, 2025, ArriVent recorded total operating expenses of 177,534 (in thousands), driven mainly by research and development expenses of 153,351 (in thousands), reflecting investment in firmonertinib and its ADC portfolio. The company reported a net loss of 166,308 (in thousands), compared with 80,488 (in thousands) in 2024, and total assets of 333,169 (in thousands), including cash, cash equivalents and investments.
Management highlighted continued progress for ARR-217, a CDH17-targeted antibody-drug conjugate in an ongoing Phase 1 trial for gastrointestinal tumors, and indicated plans to advance additional ADC candidates toward the clinic, broadening ArriVent’s focus beyond lung cancer into multiple solid tumors.
ArriVent Biopharma amendment: Sofinnova entities and two managing members report beneficial ownership of 1,696,752 shares of Common Stock, representing 4.1% of the class.
The filing amends and restates a prior statement filed on November 12, 2024 and clarifies voting and dispositive powers among SVP XI, SM XI LP, SM XI LLC, Dr. James I. Healy and Dr. Maha Katabi.
ArriVent BioPharma, Inc. is the subject of an amended ownership report showing that Infinitum Cayman Master Ltd, together with Infinitum Asset Management LLC and Infinitum Partners GP, LLC, beneficially owns 4,123,923 shares of ArriVent common stock, representing 9.9% of the outstanding class.
The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of ArriVent. Voting and investment power over these shares is reported as sole, with no shared voting or dispositive power indicated.
ArriVent BioPharma, Inc. shareholder Hillhouse Investment Management, Ltd. reported beneficial ownership of 3,929,117 shares of ArriVent common stock, representing 9.5% of the company’s outstanding shares. This reflects Hillhouse’s position as of a reference base of 41,281,361 shares outstanding on November 7, 2025.
The shares are held through affiliated entities VI Holdings Limited, VIII Holdings Limited and ARVT Holdings Limited, for which Hillhouse is the sole management company. Hillhouse reports sole voting and dispositive power over all 3,929,117 shares, and the filing is an amendment to a prior Schedule 13G.
ArriVent BioPharma’s Chief Operating Officer, Robin LaChapelle, reported receiving a stock option award covering 130,000 shares of common stock. The option, granted on February 2, 2026, has an exercise price of $22.67 per share and expires on February 2, 2036.
The award vests as to 25% of the underlying shares on February 2, 2027. The remaining shares vest in 36 equal monthly installments thereafter, conditioned on LaChapelle’s continued service with the company through each vesting date.
ArriVent BioPharma, Inc. reported that director and President of R&D Stuart Lutzker received a grant of 150,000 stock options to purchase common stock at an exercise price of $22.67 per share on February 2, 2026. These options expire on February 2, 2036.
The options vest 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments after that date, conditioned on Lutzker’s continued service through each vesting date. Following this grant, he beneficially owns 150,000 derivative securities directly.
ArriVent BioPharma’s Chief Financial Officer Winston Kung received a stock option grant reported on this Form 4. On February 2, 2026, he was awarded an option to purchase 140,000 shares of common stock at an exercise price of $22.67 per share.
The option vests over time, with 25% of the underlying shares vesting on February 2, 2027. The remaining shares vest in 36 equal monthly installments thereafter, conditioned on his continued service with the company through each vesting date. The option expires on February 2, 2036.
ArriVent BioPharma’s President and CEO, Zhengbin Yao, reported a new stock option grant. On February 2, 2026, he received an option to purchase 550,000 shares of common stock at an exercise price of $22.67 per share.
According to the filing, 25% of the option vests on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, contingent on his continued service. Following this grant, he beneficially owns 550,000 derivative securities directly.